Page 1 of 1 [ 6 posts ] 

The_Znof
Veteran
Veteran

User avatar

Joined: 14 Sep 2011
Age: 52
Gender: Non-binary
Posts: 999
Location: Vancouver Canada

12 Dec 2021, 8:07 pm

Antidepressant fluvoxamine can save COVID-19 patients, McMaster-led research shows

AUGUST 17, 2021

Quote:
The fluvoxamine trial formed part of the larger TOGETHER Trial that started in May 2020, aiming to test potential COVID-19 treatments in a community setting.

TOGETHER Trial scientists tested eight drugs, including hydroxychloroquine, metformin, kaletra and ivermectin, but only fluvoxamine had a positive effect on COVID-19.

“Fluvoxamine is the only treatment that, if administered early, can prevent COVID-19 from becoming a life-threatening illness,” said Mills, co-principal investigator for the TOGETHER Trial and a professor of McMaster’s Department of Health Research Methods, Evidence, and Impact. “It could be one of our most powerful weapons against the virus and its effectiveness is one of the most important discoveries we have made since the pandemic began.

“In addition, this cheap, easily-accessible pill is a massive boon to public health, both in Canada and internationally, allowing hospitals to avoid expensive and sometimes risky treatments.”

Costing about $4 per 10-day course, fluvoxamine could be a game-changer for poorer countries with low vaccination rates and lacking access to more advanced COVID-19 therapies, Mills said.


https://brighterworld.mcmaster.ca/artic ... rch-shows/

well what happened? :wink:



Last edited by magz on 13 Dec 2021, 6:38 am, edited 2 times in total.: Title corrected - originally "Prozac for Covid." but Luvox is not Prozac

The_Znof
Veteran
Veteran

User avatar

Joined: 14 Sep 2011
Age: 52
Gender: Non-binary
Posts: 999
Location: Vancouver Canada

12 Dec 2021, 8:16 pm

Fluvoxamine

Last Updated: April 23, 2021

https://www.covid19treatmentguidelines. ... uvoxamine/

:wink:



Matrix Glitch
Veteran
Veteran

User avatar

Joined: 21 Oct 2021
Age: 60
Gender: Male
Posts: 1,356

13 Dec 2021, 2:54 am

Is there a livestock version I can take?



The_Znof
Veteran
Veteran

User avatar

Joined: 14 Sep 2011
Age: 52
Gender: Non-binary
Posts: 999
Location: Vancouver Canada

13 Dec 2021, 10:23 am

If there was it would be all over the news by now. :jester:

btw I think it may be luvox, not prozac, the sources are all over the place on this.



theprisoner
Veteran
Veteran

User avatar

Joined: 9 Jan 2021
Age: 33
Gender: Male
Posts: 4,431
Location: Britain

13 Dec 2021, 10:27 am

So the rich get richer, and the sick get happy pills?


_________________
AQ: 27 Diagnosis:High functioning (just on the cusp of normal.) IQ:131 (somewhat inflated result but ego-flattering) DNA:XY Location: UK. Eyes: Blue. Hair: Brown. Height:6'1 Celebrity I most resemble: Tom hardy. Favorite Band: The Doors. Personality: uhhm ....(what can i say...we asd people are strange)


The_Znof
Veteran
Veteran

User avatar

Joined: 14 Sep 2011
Age: 52
Gender: Non-binary
Posts: 999
Location: Vancouver Canada

14 Dec 2021, 1:53 pm

theprisoner wrote:
So the rich get richer, and the sick get happy pills?


no, the rich get even richer. Its a long article and Im not fully up to speed on the whole story, but this Watson fellow seems a bit witch hunty, even getting into the hornse meds after it suggests waiting for more studies on before approving off label luvox.


James Watson, a statistician and data analyst at the Mahidol Oxford Tropical Medicine Research Unit who has been involved in the design and analysis of clinical trials for drugs tackling COVID-19 and other infectious diseases


Quote:

Watson tells The Scientist that one effect of the new fluvoxamine study has been to encourage other trial organizers to include SSRIs in their own studies, noting a trial he is involved with in sub-Saharan Africa as an example. “You get this positive result and then it becomes this new fashion and then all the trials want to try it out,” he says. While he supports the idea of a larger trial of fluvoxamine, for now, he says, “I definitely think this does not support changing [treatment] guidelines.”Reiersen and Lenze express a different view, saying that they want to see fluvoxamine being prescribed as a COVID-19 treatment based on current evidence. Lenze, who calls the drug “life-saving” in an email to The Scientist, notes that fluvoxamine is easy to take and has a good safety record. “Doctors can prescribe it now to reduce their patients’ risk of hospitalization and death,” he says.

“I think based on the current evidence it makes sense for physicians to go ahead and prescribe fluvoxamine for certain high risk outpatients with symptomatic COVID-19, after considering the current evidence, any potential drug interactions, and the risks & benefits specific to their patients,” agrees Reiersen, who has previously also voiced her support for the use of ivermectin, an antiparasitic drug that has yet to show efficacy against COVID-19 in well-controlled randomized clinical trials.

See “Ivermectin (Still) Lacks Support as a COVID-19 Drug”
“I look forward to seeing whether [the National Institutes of Health] adjusts their guidelines to support this,” she says of fluvoxamine, adding that she is currently collaborating with researchers at various institutions to work toward clarifying its mechanisms of action in lab studies. There could be other benefits of the drug, she suggests: “I also hope to start a randomized controlled trial using fluvoxamine to treat long COVID.”


https://www.the-scientist.com/news-opin ... data-69369

Earlier in the atricle Watson complains about the small sample size, [~50 patients total] but I see studies with small sample sizes all the time - maybe it is just my luck, but if they are still common, maybe Watson is doing a bit of cherry picking himself here - which could get interesting if his accusations of cherry picking against the study are exaggerated.